Glaucoma:
Indications for: LUMIGAN
Reduction of elevated intraocular pressure in open-angle glaucoma or ocular hypertension.
Clinical Trials:
In a 12-month clinical study of patients with open angle glaucoma or ocular hypertension with an average baseline IOP of 23.5 mmHg, the IOP-lowering effect of Lumigan 0.01% once daily (in the evening) was up to 7.5 mmHg.
Adult Dosage:
≥16yrs: 1 drop in affected eye once daily in the PM.
Children Dosage:
<16yrs: not recommended.
LUMIGAN Warnings/Precautions:
Do not exceed recommended dose. Intraocular inflammation. Aphakia. Pseudophakia with torn posterior lens capsule. Risk of macular edema. Contact lenses (remove; may reinsert lenses 15mins after administration). Pregnancy. Nursing mothers.
LUMIGAN Classification:
Prostaglandin analogue.
LUMIGAN Interactions:
Allow at least 5mins between application of other topical ophthalmic agents.
Adverse Reactions:
Conjunctival hyperemia, ocular effects (eg, edema, hemorrhage, irritation, pain, pruritus), hypertrichosis, eyelash growth, visual disturbances, increased ocular pigmentation (iris, eyelid, eyelashes; may be permanent), other eyelash changes, keratitis, infection, abnormal liver function tests.
Drug Elimination:
Renal (67%), fecal (25%). Half-life: ~45 minutes.
Generic Drug Availability:
NO
How Supplied:
Soln—2.5mL, 5mL, 7.5mL
